MedPath

a Novel Individualized Substrate Modification Approach for the Treatment of Long-standing Persistent Atrial Fibrillation

Not Applicable
Conditions
Atrial Fibrillation
Interventions
Procedure: individualized substrate modification
Procedure: stepwise ablation
Registration Number
NCT02477592
Lead Sponsor
RenJi Hospital
Brief Summary

The purpose of this study is to compare effectiveness of two substrate modification approaches in long-standing persistent atrial fibrillation patients, and hypothesized that a substrate-based, individualized substrate modification (ISM)approach should be superior to traditional stepwise ablation(SA). To the best of investigator's knowledge, this was the first study to evaluate the "real" substrate by means of electro-anatomic mapping and to perform "true" substrate modification in long standing persistent atrial fibrillation ablation(LPAF).

Detailed Description

Catheter ablation (CA) is highly effective for paroxysmal atrial fibrillation(AF), it is modestly effective for long standing persistent atrial fibrillation ablation(LPAF) even with complex or combined approaches, which is mainly attributed to the substrate underlying AF remodeling. Severity of atrial fibrosis is closely associated with clinical outcomes after CA for AF . The more atrial scars and fibrosis present, the lower the success rate for AF ablation. Patients with LPAF have many more areas with scars and fibrosis than those with paroxysmal AF or non-AF controls. The MRI delayed enhancement technique provides a non-interventional tool for evaluation of atrial fibrosis, however, it must be performed in sinus rhythm.Three-dimensional electro anatomic mapping has proven as accurate as MRI and can be performed easily during AF ablation, thus providing a good tool for evaluation of atrial substrate during LPAF ablation.

Although electro-anatomic mapping provided a desirable surrogate for delayed enhancement MRI to define AF substrate, there was an important technical issue to be considered. There were no good techniques to predict a desirable tip-tissue contact before the contact force catheter was applied. A poor tip-tissue contact could render the results of voltage mapping less reliable. On the other hand, excessively high contact force could increase the risk of steam pop and cardiac perforation during ablation. Hence it was important to use the contact force catheter to perform substrate mapping and ablation.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
220
Inclusion Criteria
  • Age ≥ 18 and ≤ 72years
  • History of LPAF for ≥1 and ≤ 5 years
  • Written informed consent provided
  • Acceptance of catheter ablation treatment
  • Acceptance of post-ablation follow-up
Exclusion Criteria
  • Prior history of catheter ablation or surgical ablation
  • Abnormal coagulation; contraindication for anti-coagulation
  • left atrium diameter ≥ 55mm
  • left atrium thrombus

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Individualized substrate modificationindividualized substrate modificationCircumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
Stepwise ablationstepwise ablationCPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
Primary Outcome Measures
NameTimeMethod
atrial fibrillation free rate on or off antiarrhythmic drugs (AADs) after initial ablation1 year
Secondary Outcome Measures
NameTimeMethod
Prevalence of recurrent atrial flutter1 year
Proportion of pulmonary vein isolation1 year
Proportion of acute pulmonary vein re-connection1 year
Total ablation time1 year
Fluoroscopy exposure time1 year
Number of participants with adverse event1 year

pericardial tamponade and thromboembolism event

Trial Locations

Locations (1)

Shanghai Jiaotong University school of medicine,Renji Hospital

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath